or Try an Advanced Search...

    Technical Analysis for KYTX - Kyverna Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 7.50 1.90% 0.14
    KYTX closed up 1.9 percent on Friday, June 28, 2024, on 4.01 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent N/A Down Down
    Historical KYTX trend table...
    Date Alert Name Type % Chg
    Volume Surge Other 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Narrow Range Bar Range Contraction 1.90%
    Wide Bands Range Expansion 1.90%
    Oversold Stochastic Weakness 1.90%
    New 52 Week Closing Low Bearish 3.16%
    Outside Day Range Expansion 3.16%
    Wide Bands Range Expansion 3.16%
    Oversold Stochastic Weakness 3.16%
    Older End-of-Day Signals for KYTX ...

       Recent Intraday Alerts

    Alert Time
    Up 5% 1 day ago
    Rose Above Previous Day's High 1 day ago
    Up 3% 1 day ago
    60 Minute Opening Range Breakout 1 day ago
    Up 2% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    KYTX Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis

    Is KYTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 20 Kyverna gains as FDA clears trial for lead therapy
    Jun 20 Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
    Jun 17 First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
    Jun 14 Kyverna stock plunges 28% amid data update on lead drug
    Jun 14 Dow Tumbles Over 200 Points; Adobe Earnings Top Views
    Jun 10 Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
    Jun 7 Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
    May 15 Kyverna Therapeutics reports Q1 GAAP EPS of -$1.12
    May 14 Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    See more KYTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 35.06
    52 Week Low 6.75
    Average Volume 651,289
    200-Day Moving Average 0.00
    50-Day Moving Average 13.31
    20-Day Moving Average 10.64
    10-Day Moving Average 7.84
    Average True Range 1.38
    RSI (14) 30.56
    ADX 22.59
    +DI 18.74
    -DI 31.05
    Chandelier Exit (Long, 3 ATRs) 12.51
    Chandelier Exit (Short, 3 ATRs) 10.88
    Upper Bollinger Bands 16.38
    Lower Bollinger Band 4.91
    Percent B (%b) 0.23
    BandWidth 107.81
    MACD Line -2.00
    MACD Signal Line -1.80
    MACD Histogram -0.1934
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 8.63
    Resistance 3 (R3) 8.61 8.21 8.44
    Resistance 2 (R2) 8.21 7.93 8.22 8.37
    Resistance 1 (R1) 7.86 7.75 8.04 7.88 8.31
    Pivot Point 7.46 7.46 7.55 7.47 7.46
    Support 1 (S1) 7.11 7.18 7.29 7.13 6.69
    Support 2 (S2) 6.71 7.00 6.72 6.63
    Support 3 (S3) 6.36 6.71 6.56
    Support 4 (S4) 6.38